Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,290 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Optimization of a dihydropyrrolopyrazole series of transforming growth factor-beta type I receptor kinase domain inhibitors: discovery of an orally bioavailable transforming growth factor-beta receptor type I inhibitor as antitumor agent.
Li HY, McMillen WT, Heap CR, McCann DJ, Yan L, Campbell RM, Mundla SR, King CH, Dierks EA, Anderson BD, Britt KS, Huss KL, Voss MD, Wang Y, Clawson DK, Yingling JM, Sawyer JS. Li HY, et al. J Med Chem. 2008 Apr 10;51(7):2302-6. doi: 10.1021/jm701199p. Epub 2008 Mar 4. J Med Chem. 2008. PMID: 18314943
Dihydropyrrolopyrazole transforming growth factor-beta type I receptor kinase domain inhibitors: a novel benzimidazole series with selectivity versus transforming growth factor-beta type II receptor kinase and mixed lineage kinase-7.
Li HY, Wang Y, Heap CR, King CH, Mundla SR, Voss M, Clawson DK, Yan L, Campbell RM, Anderson BD, Wagner JR, Britt K, Lu KX, McMillen WT, Yingling JM. Li HY, et al. J Med Chem. 2006 Mar 23;49(6):2138-42. doi: 10.1021/jm058209g. J Med Chem. 2006. PMID: 16539403
Synthesis and activity of new aryl- and heteroaryl-substituted 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole inhibitors of the transforming growth factor-beta type I receptor kinase domain.
Sawyer JS, Beight DW, Britt KS, Anderson BD, Campbell RM, Goodson T Jr, Herron DK, Li HY, McMillen WT, Mort N, Parsons S, Smith EC, Wagner JR, Yan L, Zhang F, Yingling JM. Sawyer JS, et al. Among authors: li hy. Bioorg Med Chem Lett. 2004 Jul 5;14(13):3581-4. doi: 10.1016/j.bmcl.2004.04.007. Bioorg Med Chem Lett. 2004. PMID: 15177479
Overcoming Secondary Mutations of Type II Kinase Inhibitors.
Wang X, DeFilippis RA, Yan W, Shah NP, Li HY. Wang X, et al. Among authors: li hy. J Med Chem. 2024 Jun 5. doi: 10.1021/acs.jmedchem.3c01629. Online ahead of print. J Med Chem. 2024. PMID: 38837951 Review.
Hypogonadism among HIV-positive men who have sex with men in Taiwan: Prevalence and associated factors.
Lin KY, Sun HY, Liu WD, Lin CY, Tsai MJ, Chuang YC, Li HY, Lin JW, Liu WC, Wu PY, Chen LY, Chang HY, Luo YZ, Chen YT, Li GC, Shih SR, Hung CC. Lin KY, et al. Among authors: li hy. J Microbiol Immunol Infect. 2024 May 24:S1684-1182(24)00083-5. doi: 10.1016/j.jmii.2024.05.006. Online ahead of print. J Microbiol Immunol Infect. 2024. PMID: 38816319 Free article.
3,290 results